NEW YORK–(BUSINESS WIRE)–NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of BiomX Inc. (the “Company”), each exercisable for one-half of a share of common stock, at an exercise price of $11.50 per share (the “Warrants”) — ticker symbol PHGE.WS — from the NYSE American. Trading in the Company’s Warrants will be suspended immediately. Trading in the Company’s common stock — ticker symbol PHGE — and units — ticker symbol PHGE.U — will continue on the NYSE American.
NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of the Warrants.
The Company has a right to a review of staff’s determination to delist the Warrants by a Committee of the Board of Directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the Company’s Warrants upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
Contacts
Company Contacts:
Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
[email protected]
BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
[email protected]
NYSE Contact:
NYSE Communications
[email protected]
